Louise Chen: The Street has not fully valued what global generics rivalry will mean for TEVA’s Copaxone.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares are diving nearly 15% in Wednesday’s trading session, following the news that competitor Mylan N.V.
